纤维肌痛综合征的两个表观遗传标记:一个匹配的病例对照研究
Marine Delay1, Nicolas Macian2, Christian Dualé2
1Platform of Clinical Investigation Department, Inserm CIC 1405, Clermont-Ferrand University Hospital, Clermont-Ferrand F-63000, France; Inserm 1107, Neuro-Dol, Clermont Auvergne University, Clermont-Ferrand F-63000, France.
The journal of pain
|December 7, 2025
概括
这项研究发现,两种特定的微RNA (miRs) 与女性纤维肌痛综合征 (FMS) 严重程度有关. 这些miR可以帮助分层患者,并指导个性化的FMS疗法.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 神经免疫学 神经免疫学
- 翻译医学是一种翻译医学.
背景情况:
- 微RNAs (miRs) 在生物调节中发挥作用,可能与纤维肌痛综合征 (FMS) 病理生理学有关.
- 在FMS和免疫调节中的性别差异是显著的,需要对女性患者群体进行专注研究.
研究的目的:
- 探索在纤维肌痛综合征 (FMS) 中的血微RNA概况和临床特征之间的相关性.
- 在FMS患者中识别不同的分子子组.
- 调查潜在的microRNA生物标志物用于FMS分层和个性化治疗.
主要方法:
- 血微RNA测序在113名女性FMS患者和29名健康志愿者 (HV) 上进行.
- 患有FMS的患者被分为分子群 (FM1,FM2) 和临床严重程度组.
- 生物信息学分析被用来识别失调的miR及其潜在的信号通路.
主要成果:
- 在FMS患者中发现了两个不同的分子 (FM1和FM2),FM1与HV相比显示出显著的miR失调.
- 两种特定的miRs,miR-4771和miR-2115-3p,在临床严重程度组中显著失调,与功能影响相关.
- 生物信息学表明,这些miRs参与TGF-β信号通路,可能将神经免疫通路与症状严重程度联系起来.
结论:
- 纤维肌痛综合征表现出表观遗传异质性,确定了不同的分子子组.
- miR-4771和miR-2115-3p显示出作为FMS患者分层的生物标志物的潜力.
- 这些发现表明个性化FMS疗法的新目标,尽管需要进一步验证.
相关概念视频
Pedigree Analysis
Overview
Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Sex-linked Disorders
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...


